Key statistics
On Wednesday, Matinas BioPharma Holdings Inc (MTNB:ASQ) closed at 3.29, 11.53% above the 52 week low of 2.95 set on Oct 03, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.26 |
---|---|
High | 3.35 |
Low | 3.15 |
Bid | 1.33 |
Offer | 3.30 |
Previous close | 3.23 |
Average volume | 47.94k |
---|---|
Shares outstanding | 5.02m |
Free float | 4.89m |
P/E (TTM) | -- |
Market cap | 16.50m USD |
EPS (TTM) | -5.10 USD |
Data delayed at least 15 minutes, as of Oct 09 2024.
More ▼
Announcements
- Matinas BioPharma Reports Second Quarter 2024 Financial Results and Provides a Business Update
- Matinas BioPharma to Webcast Conference Call to Discuss Second Quarter 2024 Financial Results and Provide a Business Update on August 14, 2024
- Matinas BioPharma Reports Successful Treatment of Patient with Limb-Threatening Mucor Infection in its Oral MAT2203 Compassionate/Expanded Use Access Program
- Matinas BioPharma’s Oral MAT2203 to Be Featured in Fireside Chat Hosted by A.G.P. with Antifungal Expert Dr. David S. Perlin
- New In Vitro Data Showing Matinas BioPharma’s LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024
- Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business Update
- Matinas BioPharma’s LNC Platform for the Delivery of Small Oligonucleotides Featured in Two Presentations at the ASGCT Annual Meeting
- Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2024 Financial Results and Provide a Business Update on May 9, 2024
- In Vivo Efficacy of Matinas BioPharma’s Oral MAT2203 in Pulmonary Mucormycosis Published in Journal of Antimicrobial Agents and Chemotherapy
- Matinas BioPharma Prices $10 Million Registered Direct Offering
More ▼